Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) Assets Average (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Assets Average for 5 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average rose 15.36% to $1.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 billion, a 15.36% increase, with the full-year FY2025 number at $1.0 billion, up 43.08% from a year prior.
  • Assets Average was $1.0 billion for Q4 2025 at Janux Therapeutics, down from $1.0 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.1 billion in Q1 2025 to a low of $347.2 million in Q2 2023.
  • A 5-year average of $592.8 million and a median of $389.7 million in 2021 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: dropped 7.89% in 2023, then soared 128.94% in 2024.
  • Janux Therapeutics' Assets Average stood at $385.5 million in 2021, then dropped by 4.04% to $369.9 million in 2022, then increased by 3.72% to $383.6 million in 2023, then skyrocketed by 128.94% to $878.3 million in 2024, then grew by 15.36% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for JANX's Assets Average are $1.0 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.0 billion (Q2 2025).